Rarely, as far as the trials can tell. In the two placebo-controlled Zepbound trials, dysesthesia, meaning altered or painful skin sensation, was reported by 0.2% of people on 5 mg or 10 mg and 0.4% on 15 mg. On placebo the figure was 0.1% [1]. Beyond that label line, the tirzepatide evidence is reports, not trials. One published case report describes it in a patient on tirzepatide [2].
People describe it in plain terms. A shirt collar burns, a bedsheet hurts, skin feels sunburned without sun. The medical words are dysesthesia for altered sensation and allodynia for pain from a touch that should not hurt. The trials behind the Zepbound label were designed to measure weight, not either symptom. Hair shedding is the other body complaint that arrives in the same months, and the hair-loss evidence is built on similar trial tables.
What the Zepbound trials recorded
The label pools Study 1 and Study 2, the placebo-controlled weight-reduction trials [1]. Dysesthesia is not in the main side-effect table, which lists reactions at 2% or more. It appears in the text below it, dose by dose. The rates were 0.2% at 5 mg, 0.2% at 10 mg and 0.4% at 15 mg, against 0.1% on placebo.
That is a small absolute gap. It is also a count of whatever investigators coded as dysesthesia, not a symptom survey. The label does not say how long the episodes lasted or how many people stopped the drug over them. Neither figure is published. The same limit applies to headache on the Zepbound label, where the table is the only randomized figure.
The reports behind the term allodynia
The case literature is short, and it is where the word allodynia entered the record. A 2025 case series from a Veterans Affairs system described four patients on semaglutide [3]. All four took it for obesity and developed skin pain at the 2.4 mg weekly dose. The authors reported a clear link in time, and to dose, in each case.
Two of the four stopped semaglutide, and their symptoms resolved. Two kept taking it, and one of them recovered after 4 months. The authors rated all four cases as probable on the Naranjo causality scale. They wrote that no drug mechanism had been identified. They also said it is not known whether this is a class effect.
The tirzepatide case came later. A 2025 case report described dysesthesia on semaglutide and presented what the author called a novel report in a patient taking tirzepatide [2]. The author describes the reaction as appearing dose dependent, resolving when the drug was stopped, and sometimes resolving on its own after several weeks. That is one patient. It shows the reaction can occur on tirzepatide, not how often.
What the reporting databases add
The World Health Organization database, VigiBase, was mined for these terms in a 2026 analysis [4]. Semaglutide and tirzepatide were both significantly associated with hyperesthesia, an exaggerated skin sensation. Semaglutide was also associated with dysesthesia and burning sensation. The authors describe the effect as dose dependent, with discontinuation often followed by recovery, and cases of rechallenge observed.
An analysis of the FDA’s reporting system found allodynia among 19 neurological signals for the GLP-1 class [5]. Across all of those neurological reports, the median time from starting the drug was 32 days. The authors state that these are associations, not causal findings. The same caution runs through what adverse-event reports actually list.
The dose pattern, seen on semaglutide
The clearest dose pattern comes from semaglutide, not tirzepatide. In the Wegovy 2.4 mg trials, dysesthesia occurred in 2% on the drug and 1% on placebo [6]. The label’s grouping for that line includes allodynia, sensitive skin, pain of skin and skin burning sensation.
STEP UP then tested 7.2 mg in 1,407 adults with obesity and without diabetes for 72 weeks [7]. Dysesthesia was reported by 22.9% on 7.2 mg, 6.0% on 2.4 mg and 0.5% on placebo. The efficacy side of that trial is covered in whether a higher semaglutide dose is worth it. The Zepbound label’s own dose steps, 0.2% to 0.4%, show nothing on that scale.
The Wegovy label adds what happened next at 7.2 mg [6]. Among people who reported dysesthesia, 18% did not report recovering during the trial. Of 38 who recovered and were raised back to 7.2 mg, 17 reported it again. Those are semaglutide figures. They show a pattern worth knowing, not a tirzepatide rate.
What remains unmeasured
For tirzepatide, the label reports none of three things: how long an episode lasts, whether a lower dose ends it, and whether it returns on the same dose. They are not measured. Tirzepatide stays in the body for weeks after a last dose, as how long Zepbound stays in your system explains. A report of improvement days after stopping should be read with that in mind. Compounded tirzepatide is not FDA-approved and has no trial safety data of its own.